UBS raised the firm’s price target on BrightSpring Health (BTSG) to $42 from $35 and keeps a Buy rating on the shares. BrightSpring’s Q3 results were positive with another beat and raise quarter, with management expressing optimism around this momentum continuing into 2026, with a particular emphasis on the growth prospects within its infusion business, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services, Inc.: Strong Financial Performance and Growth Prospects Justify Buy Rating
- BrightSpring Health Services, Inc.: Strong Growth Prospects and Strategic Leverage Improvement Reinforce Buy Rating
- BrightSpring Health Services Reports Strong Q3 2025 Results
- BrightSpring Health Services: Strong Fundamentals and Promising 2026 Outlook Justify Buy Rating
- BrightSpring Health reports Q3 diluted EPS 26c, consensus 33c